Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Virtu Financial LLC bought a new position in shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,959 shares of the company’s stock, valued at approximately $62,000. Virtu Financial LLC owned approximately 0.05% of Telomir Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC increased its stake in Telomir Pharmaceuticals by 259.8% during the 3rd quarter. Geode Capital Management LLC now owns 238,737 shares of the company’s stock worth $1,533,000 after buying an additional 172,382 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Telomir Pharmaceuticals by 327.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 46,406 shares of the company’s stock valued at $191,000 after acquiring an additional 35,556 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Telomir Pharmaceuticals by 40.8% during the fourth quarter. Bank of New York Mellon Corp now owns 72,295 shares of the company’s stock worth $298,000 after acquiring an additional 20,931 shares during the last quarter. State Street Corp lifted its stake in shares of Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Telomir Pharmaceuticals by 325.1% in the third quarter. Barclays PLC now owns 7,018 shares of the company’s stock valued at $45,000 after purchasing an additional 5,367 shares during the last quarter.

Telomir Pharmaceuticals Stock Down 18.2 %

NASDAQ:TELO opened at $3.23 on Tuesday. Telomir Pharmaceuticals, Inc. has a 52 week low of $3.11 and a 52 week high of $9.39. The company has a market cap of $96.13 million and a PE ratio of -5.57. The business’s 50 day moving average is $4.35 and its two-hundred day moving average is $4.71.

Telomir Pharmaceuticals (NASDAQ:TELO) last released its quarterly earnings data on Tuesday, February 4th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). As a group, sell-side analysts expect that Telomir Pharmaceuticals, Inc. will post -0.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TELO has been the topic of several analyst reports. Rodman & Renshaw began coverage on Telomir Pharmaceuticals in a report on Friday, February 21st. They set a “buy” rating and a $15.00 price objective on the stock. RODMAN&RENSHAW raised shares of Telomir Pharmaceuticals to a “strong-buy” rating in a report on Thursday, February 20th.

Telomir Pharmaceuticals Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.